Guselkumab vs Ustekinumab for stricturing Crohn's disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational cohort of adults with moderate-to-severe Crohn's disease and radiographic or endoscopic evidence of luminal strictures who are being treated with either guselkumab or ustekinumab. Patients provide consent and receive routine biologic therapy chosen by their physician while investigators collect baseline medical history and follow the treatment course. At scheduled follow-up visits investigators obtain blood, stool, and tissue samples as available and perform endoscopy, imaging, laboratory testing, symptom self-assessments, and nutritional screening. The study compares clinical symptoms, imaging and endoscopic findings, laboratory markers, and specimen-based biomarkers between the two treatment groups over time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Confirmed patients with moderate-to-severe Crohn's disease (CD), aged 18 to 80 years, receiving treatment with Guselkumab or Ustekinumab.
* Presence of obstructive symptoms consistent with chronic or subacute intestinal obstruction within the past 8 weeks, with confirmed postprandial abdominal pain attributable to strictures, with the exclusion of: ① mild to moderate pain (postprandial abdominal pain or abdominal pain exacerbated by diet, ameliorated with abdominal bowel sounds) without nausea, vomiting or abdominal colic; ② dietary restrictions unrelated to abdominal pain.
* Evidence of definite luminal strictures caused by the disease itself confirmed by radiographic imaging or endoscopic examination, i.e., meeting any of the following criteria:

  1. Enteric computed tomography (CT): Presence of intestinal strictures on enteric CT, with two of the three following findings at the stricture site compared with the adjacent proximal bowel: ① a \>50% reduction in luminal diameter; ② a \>25% increase in bowel wall thickness; ③ pre-stenotic dilation \>2.5 cm.
  2. Endoscopic examination: Intestinal strictures that are impassable to the endoscope.

Exclusion Criteria:

* Patients with severe disease requiring emergency surgery or endoscopic therapeutic intervention, or those judged by the attending clinician to need a switch of medication or elective surgery within 2 months, such as those with acute severe intestinal obstruction, perforation, intra-abdominal abscess, intra-abdominal adhesion, and other conditions leading to obstruction, hemorrhage, infection, etc.
* Intestinal obstruction, intra-abdominal abscess, isolated intestinal stricture and other lesions secondary to surgery.
* Patients who have received definitive therapeutic interventions for strictures within the past 6 months, such as endoscopic balloon dilation, stricture incision, intestinal stricture plasty, surgical/manual anal dilatation, etc.
* Severe patients who remain unable to take oral intake despite enteral nutrition (EN) administration for more than 2 months.
* Patients who have used Guselkumab (GUS), Ustekinumab (UST) or other IL-23 antagonists within the past 12 months; or those with contraindications to GUS/UST, or intolerance to the study medications due to other causes (e.g., allergy to IL-23 antagonists).
* Patients with contraindications to small intestinal computed tomography (CT), such as contrast media allergy.
* Patients with relative contraindications to biological agents, such as active tuberculosis with a positive chest X-ray for pulmonary tuberculosis or a strongly positive tuberculin skin test; a history of myocardial infarction, heart failure or demyelinating neurological diseases within the past 5 years.
* Patients currently suffering from solid tumors, with a past history of lymphoma or melanoma, or undergoing chemotherapy or radiotherapy.
* Patients complicated with intestinal dysplasia (e.g., diagnosed with short bowel syndrome), colostomy or colorectal neoplasms.
* Patients complicated with active massive gastrointestinal hemorrhage, severe hepatic and renal dysfunction, active bacterial or viral infection, shock, as well as intractable vomiting and severe malabsorption syndrome.
* Pregnant or lactating patients.
* Patients with severe hemodynamic and vital sign instability, or those with rapidly progressive or end-stage diseases.
* Patients with psychiatric disorders, or those with insufficient educational level to fully understand the study content or unable to cooperate with the completion of the study.

Where it's running

• Second Affiliated Hospital, School of Medicine, Zhejiang University
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Yan Chen
• Email: chenyan72_72@zju.edu.cn
• Phone: 86+13757118653

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating Ustekinumab for Treating Stricturing Crohn's Disease

  This study is testing if ustekinumab can help people with moderate-to-severe Crohn's disease who have blockages in their intestines feel better over a two-year period.

  Recruiting at 8 sites Second Affiliated Hospital, Zhejiang University, School of Medicine · Beijing, Beijing Municipality and 7 other locations · NCT05387031

• Guselkumab after Ustekinumab in adults with moderate-to-severe psoriasis in routine care

  This study looks at how well guselkumab works for people with moderate-to-severe psoriasis after switching from ustekinumab in everyday clinical practice.

  Recruiting Janssen-Cilag Kft. · Budapest · NCT07746583

• BDHK-2009 safety test in healthy adults

  This early-stage test checks if BDHK-2009 tablets are safe and tolerable in healthy adults aged 18–55 compared with placebo.

  Recruiting Phase 1 Benethera (Shaoxing) Biotechnology Co., Ltd. · Hangzhou, Zhejiang · NCT07632573

• Guselkumab for adults with Crohn's disease after ustekinumab failure

  This study will try guselkumab for adults with moderate to severe Crohn's disease who did not respond to or could not tolerate ustekinumab to see if they reach remission after 52 weeks.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07487480

• Maternal and infant microbiome links to infant gut inflammation and pregnancy outcomes in people with IBD

  This project will see if mothers' microbiomes, diets, and breastmilk are linked to infant gut inflammation (measured by fecal calprotectin) in pregnant people with and without IBD.

  Recruiting University of British Columbia · Vancouver, British Columbia and 1 other locations · NCT07385807

• Infliximab plus the Crohn's Disease Exclusion Diet for children with Crohn's disease

  This will test whether starting a Crohn's Disease Exclusion Diet at the same time as infliximab helps children with moderate-to-severe Crohn's disease get better and stay in remission.

  Recruiting University of British Columbia · Vancouver, British Columbia · NCT07314606

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.